BioRegenerative Sciences Stem Cell-Based Anti-Aging Cosmeceuticals
Dr. Greg Maguire, Paul Franck, and Peter Friedman, founders of BioRegenerative Sciences, Inc., a privately owned stem cell therapeutics corporation headquartered in San Diego, CA, USA, announced today the release of BRS’s anti-aging cosmeceutical line of products, including Vital Serum, Eye Serum, and Moisturizing Night Cream. BioRegenerative Sciences’ studies of the cosmeceuticals demonstrated that the three anti-aging products were able to reverse the effects of aging on the appearance of the skin. According to Dr. Greg Maguire, CEO and Chief Scientific Officer of BRS, “Vital Serum, Eye Serum, and Moisturizing Night Cream restore the biochemical properties of the skin to a healthy state, and therefore give the skin a much more youthful appearance.”
Peter Friedman, CBO of BRS, said that “BRS’s new cosmeceutical line is an easily applied topical group of products that replaces in the skin what was present in the normal, healthy tissue.” Dr. Rita Friedman, a member of the Scientific Advisory Board, also added, “Vital Serum uses BRS’s patented core technology, known as S2RM TechnologyTM where stem cell released molecules from multiple stem cell types are used to formulate the products.” Debra McCarthy, R.N, another member of the Scientific Advisory Board, further stated that “the molecules comprising the S2RM TechnologyTM replace the multitude of molecules that have been lost in the skin due to aging, and even women who use Botox experience a dramatic improvement in their skin, and find that they use Botox less often.”
Paul Franck concluded by saying, “The launch of BRS’ stem cell cosmeceutical line has so captured the imagination of the attendees at the A4M Congress that we sold out of our products in just two days.” Vital Serum, Eye Serum, and Moisturizing Night Cream can be purchased online at: www.bioregenerativesciences.com.
See Also:
If you enjoyed this post, please consider leaving a comment, subscribe to the feed and get future articles delivered to your feed reader or follow us on Twitter.
Comments
No comments yet.
Leave a comment